Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products
Swiss firm Lonza is taking its investment in China to the next level with a manufacturing upgrade to its key site in Guangdong Province.
Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.
What are the challenges and best practices in quality control for difficult-to-inspect products?
Has pharma fully acknowledged the power of rapid-dissolve tablet technologies?
by Sabin Metal
Precious metals-bearing catalysts are essential in some pharma processes – but, once they’re spent, they still hold value.
How to streamline a rapidly expanding field? Joe Garrity of Lonza discusses the pain points and easily missed fixes.
How can we maximize the potential and production of potentially life-saving therapies?
Veronika S Wills
How a holistic approach to horseshoe crab sustainability will allow the industry to maintain stocks while protecting patients.
Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.
Global regulators attended a virtual workshop on second generation COVID-19 vaccines – here’s what they talked about.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
X2: Researchers United
Autoinjectors: Through Thick and Thin
Staying on the Track to Eradication